License was Nuvation Bio’s largest product and service line in fiscal 2025, bringing in $76.48M of $128.00M (60%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Product | — | $49.33M |
| License | $15.75M | $76.48M |
| Royalty Revenue | — | $2.20M |
| Total | $15.75M | $128.00M |
Nuvation Bio brought in $128.00M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Nuvation Bio regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $15.75M. License was the largest at $76.48M (59.7%), ahead of Product at $49.33M (38.5%) and Royalty Revenue at $2.20M (1.7%).
Nuvation Bio began breaking out Product in fiscal 2025 and Royalty Revenue in fiscal 2025.
Nuvation Bio (NUVB) reports its revenue by product and service. In fiscal 2025, License was its largest product and service line, bringing in $76.48M (59.7% of the total), followed by Product at $49.33M (38.5%).
License was Nuvation Bio's largest product and service line in fiscal 2025, bringing in $76.48M, or 59.7% of the $128.00M total across its three product and service lines.
Every figure comes from Nuvation Bio's annual financial filings, as reported. Each line keeps the name Nuvation Bio gives it, and years follow its fiscal calendar.
Nuvation Bio's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.